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In this issue of Neuron, Griciuc et al. (2013) investigate the Alzheimer’s disease risk gene, CD33. AD brains
have increased CD33 and CD33-positive microglia. Mice lacking CD33 have less AD pathology suggesting
a role of microglia for Ab clearance and development of future therapies.All symptomatic Alzheimer’s patients and
one-third of cognitively intact persons
over age 65 have biomarker evidence of
cerebral amyloidosis. One presumes,
therefore, that stimulating amyloid clear-
ance would help maximize the therapeu-
tic reduction of neuropathology to prevent
or arrest neurodegeneration and cognitive
failure. Autosomal-dominant familial Alz-
heimer’s disease (FAD) is rare and is
attributable to misprocessing of the amy-
loid precursor protein (APP) to generate
excessive or mutant hyperaggregable
Ab42 which, in turn, serves as a ‘‘seed’’
for initiation of Ab fibrillogenesis and olig-
omerization in the brain interstitium. Some
Ab assembly states are believed to be
especially responsible for progression to
neurofibrillary tangle formation and neu-
rodegeneration. While research on poten-
tial AD treatments has focused on many
important discoveries centered around
mutations linked with FAD, in most peo-
ple, no mutations exist that enable perfect
prediction on an individual basis of
those destined to develop more common
sporadic forms of AD (for review, see
Gandy and DeKosky, 2013).
Nonneuronal CNS cells such as micro-
glia, the brain’s intrinsic phagocytes, are
beginning to take center stage as we
advance our understanding of the molec-
ular pathogenesis of common, late onset,
sporadic AD. Several new papers,
including one by Griciuc et al. in this issue
of Neuron, shift the focus of AD research
to the (patho)physiological role of micro-
glia in AD. Griciuc et al. (2013) show that
the microglial molecule CD33, an immu-
noglobulin-like cell-surface protein, in-
hibits Ab clearance in cell culture and in
transgenic mouse brain. CD33 has beengenetically linked to AD (Naj et al., 2011),
instantly providing disease relevance to
the molecule. Griciuc et al. (2013) also
show that human AD brain tissue contains
excess CD33, suggesting that dysregula-
tion of CD33 plays a role in disease path-
ogenesis. This result may provide a
molecular explanation for the Ab-medi-
ated dysfunction of microglia evidenced
by the failure of microglia to reduce Ab
burden in a transgenic mouse model of
AD (Krabbe et al., 2013), ultimately result-
ing in microglial senescence (Miller and
Streit, 2007).
Wholesale ablation of microglia in AD
transgenic mice (at least for a limited
period of time) has no obvious effect on
plaque burden, arguing against their crit-
ical importance in disease pathogenesis
(Grathwohl et al., 2009). While this study
was limited by the model-dependent
inability to assess the consequences of
microglia ablation on AD pathology for a
prolonged period or to differentiate
effects of various pathogenic Ab species,
Grathwohl et al. (2009) fuelled further in-
vestigations on the role(s) of microglia on
AD pathology. Recent papers show that
inhibition of interleukins 12 and 23 (Vom
Berg et al., 2012) or genetic deficiency of
NALP3, a component of the inflamma-
some (Heneka et al., 2013) led to a sub-
stantial reduction of AD pathology illus-
trating how microglia take on multiple,
distinct roles during the course of AD.
Another recent discovery also linksmicro-
glia to AD via the molecule CR1. Loss of
CR1modulates the impact of the apolipo-
protein E ε4 (APOE ε4) allele on brain
fibrillar amyloid burden and indicates
that microglial dysfunction can be geneti-
cally linked to AD (Thambisetty et al.,Neuron2013). Surprisingly, those patients with a
riskyCR1 genotype and anAPOE ε4 allele
have an increased risk for Alzheimer’s, yet
their fibrillar amyloid burden is reduced in
comparison to the APOE ε4 subjects that
lack the risky allele. Therefore, although
the molecular explanation for CR1-asso-
ciated AD remains to be revealed, these
studies suggest that microglia may be
helpful or harmful, either alternately or
even simultaneously. After migrating
through the interstitial space of the brain
to reach a nascent Ab deposit, the
balance between beneficial versus harm-
ful effects is unpredictable and may vary
according to individual factors. The most
straightforward model is that microglia
are beneficial when they keep pace with
Ab aggregate accumulation. Once micro-
glia are poisoned by Ab, and/or once the
Ab deposit exceeds a size that would
permit its engulfment by microglia, they
may now facilitate or instigate neuronal
dysfunction and disease progression,
evolving from rescuer to murderer. This
does not exclude the possibility that Ab
per se is also directly neurotoxic; the alter-
native pathways—namely intrinsic Ab
neurotoxicity, indirect neurotoxicity of
microglia in the presence of Ab and Ab-
driven microglial dysfunction—are not
mutually exclusive but may rather act in
concert to exacerbate AD pathology.
As a result of this revelation, it is clear
that interference with microglial function
could be beneficial, harmful, or both,
depending on the timing and/or duration
of intervention. Though inhibition or abla-
tion of microglia at late stages of AD had
no obvious effect on plaque burden
(Grathwohl et al., 2009), the situation is
quite different at early time points, when78, May 22, 2013 ª2013 Elsevier Inc. 575
Figure 1. A Subnetwork of Complement System Molecules from a
Bayesian Brain Immune and Microglia Module Contains CD33 and
TYROBP
This module correlates with multiple late-onset AD clinical covariates and is
enriched for immune functions and pathways related to microglia activity.
The complement network is derived frommultiscale analysis of genetic linkage
information and AD brain gene expression information. The subnetwork shown
here is derived from a subgroup of genes related to complement. MHC, Fc,
cytokine, and toll-like receptor networks are also part of the module but are
not shown. Core family members are shaded darkly, whereas square nodes
denote literature-supported nodes (at least two PubMed abstracts implicating
the gene or final protein complex in late-onset AD [LOAD] or a model of LOAD).
Labeled nodes are either highly connected in the original network, literature-
implicated LOAD genes, or core members of one of the five immune families.
Node size is proportional to connectivity in themodule (fromZhang et al., 2013,
with permission).
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Previewsmicroglia appear to support
both clearance of AD pathol-
ogy and exacerbation of Ab
toxicity. This means that
microglia-targeted therapies
must be finely targeted, pre-
cisely timed, and carefully
modulated at the molecular
level. Existing drugs that
could be aimed, e.g., at
increasing the phagocytic
activity of microglia include
the peroxisome proliferator-
activated receptor g (PPARg)
agonist pioglitazone and a
novel selective PPARa/g
modulator, DSP-8658 (Ya-
manaka et al., 2012), as
well as the mixed acetylcho-
linesterase inhibitor-nicotinic
agonist galantamine (Takata
et al. 2010), which is currently
used in the symptomatic
treatment of AD. Moreover,
there is still much to learn
about microglia when pre-
cisely assessing their roles
during therapeutic manipula-
tions such as Ab immuno-
therapy. There will be equal
interest in dissecting which
effects are truly conferred by
CNS resident microglia or
by their myeloid counterpartsentering the brain during the course of AD
(an issue of intense debate in the field;
e.g., Prinz et al., 2011). Considering the
prospect of potential cell-based interven-
tional approaches, these studies should
result in exciting and crucial insights.
CD33 now joins this new class of micro-
glia-related molecules for possible evalu-
ation in human clinical trials. Griciuc et al.
(2013) establish the benefit of genetic
CD33 deficiency. The assessment of
drugs that safely reduce CD33 levels
(e.g., anti-CD33 antibodies) is the obvious
next goal. Along this line, the success re-
ported by Vom Berg et al. (2012) takes us
beyond genetic deletion and on to a con-
crete example of immunotherapeutic
inhibition of IL-12/23, providing proof-of-
principle evidence that relevant microglial
pathways can indeed be viable thera-
peutic targets.
Two other recent papers link a known
microglial Ab clearing molecule, TREM2,
to Alzheimer’s disease (Guerreiro et al.,576 Neuron 78, May 22, 2013 ª2013 Elsevier2013; Jonsson et al., 2013). Rounding
out this collection of new and emerging
AD/microglia publications is a fascinating
and unconventional ‘‘multiscale’’ genetics
study that implicates an AD link for
TYROBP, a microglial molecule linked to
both TREM2 and CD33 (Zhang et al.,
2013). Thus, the first Alzheimer’s network
is born, and, unlike autosomal dominant
FAD, the focus of this network is onmicro-
glia (Figure 1), not on Ab speciation or
generation.
The implications of this explosion of
AD/microglia papers are profound. First,
the longstanding questions about
whether microglia are important in AD
and in Ab clearance would appear to be
put to rest. Second, we have new poten-
tial therapeutic opportunities for small
molecule discovery, among the first
candidate targets for small molecules
that might be employed to accelerate
Ab clearance. Third, these AD/microglia
studies describe molecules that defineInc.a new Alzheimer’s network
as well as the pathways that
are contained therein. Zhang,
Schadt, and their colleagues
have suggested that such
pathways and networks as
linked entities might consti-
tute complex drug ‘‘mega-
targets’’ and that superior
AD drugs might result from
a search for drugs that cor-
rect entire networks or sub-
networks by acting on their
hubs or ‘‘drivers’’ (Zhang
et al., 2013). Lastly, the novel
multiscale analysis of Zhang
et al. (2013), heretofore
untested in AD, has been
instantly validated by virtue
of its inclusion of two
microglial genes, CD33 and
TREM2, linked to AD by
more conventional genetic
approaches. Undoubtedly,
this eruption of AD/micro-
glial genes will stimulate
new interest in these cells
and pathways. ‘‘The more,
the merrier’’ always applies
in the case of drug targets,
and this CD33-TREM2-
TYROBP network and its
component pathways as
well as IL-12/23 signalingmolecules, represent true groundbreak-
ing progress. The pathways defined by
these molecules are the first clues based
on human disease genetics since the
cloning of presenilin 1 in 1995, and the
first clues ever to emerge solely from
studies of common forms of late onset,
sporadic AD. The implication is that
Zhang et al. (2013) may point the way
to new drug discovery efforts in AD as
has already been true in peripheral in-
flammatory diseases. A new iteration of
multiscale analysis focusing on early
stage AD is underway, as is whole
exome sequencing of the DNA from 50
patients with common, late onset, spo-
radic AD. One would predict that, in
both of these gene hunts, microglial
molecules—mere bit players just 6
months ago—may emerge as marquee
stars in the pathogenesis of AD wherein
they serve as essential, dynamic, and
Janus-like components of the amyloid
hypothesis.
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In this issue of Neuron, Yin et al. (2013) demonstrate that overexpression of Neuregulin 1 causes synaptic
dysfunction and schizophrenia-like behavioral deficits. These abnormalities can be reverted by restoring
normal levels of Neuregulin 1, opening possibilities for the treatment of mental disease.Schizophrenia is a severe mental illness
that affects approximately 1% of the
population worldwide. Genetic factors
play a major role in the etiology of
schizophrenia, with an estimated herita-
bility of around 80%. Genetic variation
in Neuregulin 1 (NRG1) has been
repeatedly linked to the disorder in
multiple human populations. In partic-
ular, more than 80 single nucleotide
polymorphisms localized in noncoding
regions of this gene have been identified
(Mei and Xiong, 2008). These observa-
tions led to the hypothesis that expres-sion of NRG1 might be altered in
schizophrenia.
Alternative splicing of NRG1 generates
more than 30 isoforms classified in six
different types (I to VI) depending on their
structure (Mei and Xiong, 2008). They all
share an epidermal growth factor (EGF)-
like domain, which is required for the
activation of several members of the
ErbB family of receptor tyrosine kinases.
In schizophrenia, the expression of partic-
ular isoforms of NRG1 seems altered,
although reports are contradictory. For
example, several studies reported areduction in the levels of the isoform 1
alpha of NRG1 in the brain of schizo-
phrenia patients (e.g., Bertram et al.,
2007), while others showed elevated
levels of NRG1 in a particular risk haplo-
type (e.g., Weickert et al., 2012). Consis-
tent with this later view, several other
studies have shown increased NRG1
mRNA and protein levels in the hippo-
campus and prefrontal cortex of schizo-
phrenia patients (Hashimoto et al., 2004;
Petryshen et al., 2005). These contradic-
tory findings have been surprisingly repli-
cated in mice: both loss and gain of NRG178, May 22, 2013 ª2013 Elsevier Inc. 577
